Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.
Anti thyroglobulin antibodies
Lobectomy
Personalized medicine
Quality of Life
Thyroid cancer
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
28
03
2024
accepted:
29
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile. We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment. Eighty-two patients followed for a median of 2.3 years (0.5-7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response. In a developing country, TL is an adequate option for appropriately selected DTC patients.
Identifiants
pubmed: 38874828
doi: 10.1007/s12020-024-03905-1
pii: 10.1007/s12020-024-03905-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
N. Hirshoren, K. Kaganov, J.M. Weinberger, B. Glaser, B. Uziely, I. Mizrahi et al. Thyroidectomy practice after implementation of the 2015 American Thyroid Association Guidelines on surgical options for patients with well-differentiated thyroid carcinoma. JAMA Otolaryngol. Head Neck Surg. 144(5), 427–432 (2018)
doi: 10.1001/jamaoto.2018.0042
pubmed: 29596551
pmcid: 5876852
S. Chan, K. Karamali, A. Kolodziejczyk, G. Oikonomou, J. Watkinson, V. Paleri, I. Nixon, D. Kim, Systematic review of recurrence rate after hemithyroidectomy for low-risk well-differentiated thyroid cancer. Eur. Thyroid J. 9(2), 12 (2020).
doi: 10.1159/000504961
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2), 109–142 (2006)
doi: 10.1089/thy.2006.16.109
pubmed: 16420177
R.M. Tuttle, A.S. Alzahrani, Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J. Clin. Endocrinol. Metab. 104(9), 4087–4100 (2019)
B.M. Barney, Y.J. Hitchcock, P. Sharma, D.C. Shrieve, J.D. Tward, Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 33(5), 645–649 (2011)
doi: 10.1002/hed.21504
pubmed: 20687168
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
E. Song, M. Han, H.S. Oh, W.W. Kim, M.J. Jeon, Y.M. Lee et al. Lobectomy is feasible for 1–4 cm papillary thyroid carcinomas: a 10-year propensity score matched-pair analysis on recurrence. Thyroid 29(1), 64–70 (2019)
doi: 10.1089/thy.2018.0554
pubmed: 30375260
D. Matsuura, A. Yuan, V. Harris, A.R. Shaha, R.M. Tuttle, S.G. Patel et al. Surgical management of low-/intermediate-risk node negative thyroid cancer: a single-institution study using propensity matching analysis to compare thyroid lobectomy and total thyroidectomy. Thyroid 32(1), 28–36 (2022)
doi: 10.1089/thy.2021.0356
pubmed: 34861772
pmcid: 8792497
R.M. Tuttle, Controversial issues in thyroid cancer management. J. Nucl. Med. 59(8), 1187–1194 (2018)
doi: 10.2967/jnumed.117.192559
pubmed: 29653980
pmcid: 6071505
I.J. Nixon, I. Ganly, S. Patel, F.L. Palmer, M.M. Whitcher, R.M. Tuttle et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150(6), 1242–1249 (2011)
doi: 10.1016/j.surg.2011.09.007
pubmed: 22136847
F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, M.D. da Cruz, F. Dias et al. Thyroid lobectomy is associated with excellent clinical outcomes in properly selected differentiated thyroid cancer patients with primary tumors greater than 1 cm. J. Thyroid Res. 2013, 398194 (2013)
doi: 10.1155/2013/398194
pubmed: 24455413
pmcid: 3884614
M. Zerey, A.S. Prabhu, W.L. Newcomb, A.E. Lincourt, K.W. Kercher, B.T. Heniford, Short-term outcomes after unilateral versus complete thyroidectomy for malignancy: a national perspective. Am. Surg. 75(1), 20–24 (2009)
doi: 10.1177/000313480907500104
pubmed: 19213391
A. Hauch, Z. Al-Qurayshi, G. Randolph, E. Kandil, Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann. Surg. Oncol. 21(12), 3844–3852 (2014)
doi: 10.1245/s10434-014-3846-8
pubmed: 24943236
P.W. Rosario, G.F. Mourão, M.R. Calsolari, Apparently intrathyroid papillary thyroid carcinoma >1 and ≤4 cm: is the need for completion thyroidectomy common among patients submitted to lobectomy? Clin. Endocrinol. 85(1), 150–151 (2016)
doi: 10.1111/cen.13034
R. Olmos, J. Lopez, F. Donoso, M. Ruiz-Esquide, T. Zegers, L. Mosso et al. Management of thyroid nodules and thyroid cancer with lobectomy: experience of a multidisciplinary team. Rev. Chil. Endocrinol. Diabetes 13(3), 118–124 (2020)
D.P. Momesso, F. Vaisman, S.P. Yang, D.A. Bulzico, R. Corbo, M. Vaisman et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J. Clin. Endocrinol. Metab. 101(7), 2692–2700 (2016)
doi: 10.1210/jc.2015-4290
pubmed: 27023446
pmcid: 6287503
L.F. Zavala, M.I. Barra, R. Olmos, M. Tuttle, H. González, N. Droppelmann et al. In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation. Arch. Endocrinol. Metab. 63(3), 293–299 (2019)
pubmed: 31038590
pmcid: 10522203
S. Leboulleux, M.J. Schlumberger, I. Borget, Thyroidectomy without radioiodine in low-risk thyroid cancer. Reply. N. Engl. J. Med. 386(22), 2155 (2022)
pubmed: 35648717
I.J. Nixon, I. Ganly, S.G. Patel, F.L. Palmer, M.M. Whitcher, R.M. Tuttle et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 151(4), 571–579 (2012)
doi: 10.1016/j.surg.2011.08.016
pubmed: 22001636
F. Vaisman, A. Shaha, S. Fish, R. Michael Tuttle, Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin. Endocrinol. 75(1), 112–119 (2011)
doi: 10.1111/j.1365-2265.2011.04002.x
W.P. Kluijfhout, J.D. Pasternak, F.T. Drake, T. Beninato, W.T. Shen, J.E. Gosnell et al. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery 161(1), 127–133 (2017)
doi: 10.1016/j.surg.2016.05.056
pubmed: 27855968
Z. Al-Qurayshi, M.A. Shama, G.W. Randolph, E. Kandil, Minimal extrathyroidal extension does not affect survival of well-differentiated thyroid cancer. Endocr. Relat. Cancer 24(5), 221–226 (2017)
doi: 10.1530/ERC-16-0509
pubmed: 28249964
R.S.R. Woods, C.W.R. Fitzgerald, C. Valero, J. Lopez, L.G.T. Morris, M.A. Cohen et al. Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: is lobectomy enough? Surgery 173(1), 246–251 (2023)
doi: 10.1016/j.surg.2022.05.045
pubmed: 36257862
G.W. Randolph, Q.Y. Duh, K.S. Heller, V.A. LiVolsi, S.J. Mandel, D.L. Steward et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22(11), 1144–1152 (2012)
doi: 10.1089/thy.2012.0043
pubmed: 23083442
M.J. Jeon, J.H. Yoon, J.M. Han, J.H. Yim, S.J. Hong, D.E. Song et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur. J. Endocrinol. 168(2), 219–225 (2013)
doi: 10.1530/EJE-12-0744
pubmed: 23161752
D. Beom Heo, Y. Piao, J. Hee Lee, S.H. Ju, H.S. Yi, M. Su Kim et al. Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis. Oral Oncol. 134, 106115 (2022)
doi: 10.1016/j.oraloncology.2022.106115
pubmed: 36108524
C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97(8), 2748–2753 (2012)
doi: 10.1210/jc.2012-1123
pubmed: 22679061
K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, A.K. Stewart, D.P. Winchester, M.S. Talamonti et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg. 246(3), 375–381 (2007).
doi: 10.1097/SLA.0b013e31814697d9
pubmed: 17717441
pmcid: 1959355
I.D. Hay, C.S. Grant, E.J. Bergstralh, G.B. Thompson, J.A. van Heerden, J.R. Goellner, Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 124(6), 958–964 (1998).
doi: 10.1016/S0039-6060(98)70035-2
pubmed: 9854569
Y.J. Li, Y.Z. Wang, Z.B. Yi, L.L. Chen, X.D. Zhou, Comparison of completion thyroidectomy and primary total surgery for differentiated thyroid cancer: a meta-analysis. Oncol. Res. Treat. 38(10), 528–531 (2015)
doi: 10.1159/000440690
pubmed: 26451702
M.A. Gulcelik, L. Dogan, G.G. Akgul, E.H. Güven, N. Ersöz Gulcelik, Completion thyroidectomy: safer than thought. Oncol. Res. Treat. 41(6), 386–390 (2018)
doi: 10.1159/000487083
pubmed: 29734197
P.W. Rosário, T.A. Fagundes, S. Purisch, [Treatment of papillary microcarcinoma of the thyroid]. Arq. Bras. Endocrinol. Metabol. 48(6), 855–860 (2004)
doi: 10.1590/S0004-27302004000600012
pubmed: 15761560
S. Xu, H. Huang, X. Zhang, Y. Huang, B. Guan, J. Qian et al. Predictive value of serum thyroglobulin for structural recurrence following lobectomy for papillary thyroid carcinoma. Thyroid 31(9), 1391–1399 (2021)
doi: 10.1089/thy.2021.0209
pubmed: 34340593
J.W. Cho, Y.M. Lee, Y.H. Lee, S.J. Hong, J.H. Yoon, Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. Clin. Endocrinol. 89(1), 100–109 (2018)
doi: 10.1111/cen.13721
S. Park, W.G. Kim, M. Han, M.J. Jeon, H. Kwon, M. Kim et al. Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study. Thyroid 27(9), 1164–1170 (2017)
doi: 10.1089/thy.2017.0177
pubmed: 28699428
S. Park, M.J. Jeon, H.S. Oh, Y.M. Lee, T.Y. Sung, M. Han et al. Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer. Thyroid 28(8), 997–1003 (2018)
doi: 10.1089/thy.2018.0046
pubmed: 29845894
A. Ritter, A. Mizrachi, G. Bachar, I. Vainer, I. Shimon, D. Hirsch et al. Detecting recurrence following lobectomy for thyroid cancer: role of thyroglobulin and thyroglobulin antibodies. J. Clin. Endocrinol. Metab. 105(6), 2145–2151 (2020)
L. Giovanella, L. Ceriani, M.L. Garo, Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis. Clin. Chem. Lab. Med. 60(7), 1091–1100 (2022)
doi: 10.1515/cclm-2022-0154
pubmed: 35475431
L. Rosato, N. Avenia, P. Bernante, M. De Palma, G. Gulino, P.G. Nasi et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J. Surg. 28(3), 271–276 (2004)
doi: 10.1007/s00268-003-6903-1
pubmed: 14961204
E. Kandil, B. Krishnan, S.I. Noureldine, L. Yao, R.P. Tufano, Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications. ORL J. Otorhinolaryngol. Relat. Spec. 75(1), 6–17 (2013)
doi: 10.1159/000345498
pubmed: 23486083
S. Xu, Y. Huang, H. Huang, X. Zhang, J. Qian, X. Wang et al. Optimal serum thyrotropin level for patients with papillary thyroid carcinoma after lobectomy. Thyroid 32(2), 138–144 (2022)
doi: 10.1089/thy.2021.0404
pubmed: 34617446
P.J. Bongers, C.A. Greenberg, R. Hsiao, M. Vermeer, M.R. Vriens, M.F. Lutke Holzik et al. Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. Surgery 167(1), 94–101 (2020)
doi: 10.1016/j.surg.2019.04.060
pubmed: 31623853
H. Tala, R. Diaz, J.M. Dominguez, P. Pineda, R. Olmos, F. Munizaga et al. Protocolo clínico cáncer diferenciado de tiroides http://soched.cl/guias/PROTOCOLO-CLINICO-CANCER-DIFERENCIADO-TIROIDES.pdf2020 [Available from: http://soched.cl/guias/PROTOCOLO-CLINICO-CANCER-DIFERENCIADO-TIROIDES.pdf (2020).